Navigation Links
Orchid Cellmark to Present at the 2009 Bank of America Health Care Conference on May 13th
Date:4/29/2009

PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc., (Nasdaq: ORCH), today announced that Thomas A. Bologna, President and Chief Executive Officer of Orchid Cellmark, is scheduled to present at the 2009 Bank of America Health Care Conference in New York City on Wednesday, May 13, 2008 at 4:00 p.m. EDT

Mr. Bologna will provide a brief corporate overview and discuss the company's recent and ongoing progress. A link to the live webcast of Mr. Bologna's presentation will be available in the Investors/Calendar of Events section of the company's website at http://www.orchid.com. The webcast will be archived through May 29, 2009.

About Orchid Cellmark

Orchid Cellmark (Nasdaq: ORCH) is a leading international provider of DNA testing services primarily for forensic and family relationship applications. Orchid Cellmark is one of the largest providers of forensic DNA testing services and its DNA results are used by the criminal justice system to assist with the identification of perpetrators, the exclusion of suspects and the exoneration of wrongfully convicted individuals. The company provides DNA family relationship testing to numerous child services organizations and individuals seeking to verify parentage. Orchid Cellmark also serves immigration and security authorities for DNA testing of individuals. In the agriculture field, the company provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these areas reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the company's reputation for exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at www.orchidcellmark.com.

All statements in this press release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to the ability to replace the work we previously provided under a subcontractor arrangement, the implementation of government contracts, growing through acquisitions, the potential value of the "mega tender", our potential success in the U.K. National Procurement Plan, expansion of our U.K. facilities, the opportunity for work related to all-arrestee legislation, the potential of property crime testing, operating efficiencies, technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark's products and services, dependence on government funding, competition, intellectual property of others, patent protection, litigation, and the timing and amount of contracts put up for bid. These risks and other additional factors affecting these statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.


'/>"/>
SOURCE Orchid Cellmark Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Orchid Cellmark Appoints James F. Smith Chief Financial Officer
2. Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1, 2007
3. Orchid Cellmark to Purchase ReliaGene Technologies, Inc.
4. Orchid Cellmark Applauds Expansion of Federal Forensic DNA Identity Testing to Include All Arrestees
5. Orchid Cellmark to Announce First Quarter 2008 Financial Results on May 8, 2008
6. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
7. Orchid Cellmark to Announce Third Quarter 2008 Financial Results on October 30, 2008
8. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
9. Avicena Group to Present at Noble Financial Conference
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2016)... ... May 17, 2016 , ... DryLet, LLC, ... applications, announced today it will be showcasing ManureMagic™ at booth V1061 at the ... in the Wall Street Journal last year and more recently made news as ...
(Date:5/17/2016)... York, NY (PRWEB) , ... May 17, 2016 , ... ... Month, buildings, bridges, and monuments across the globe will show their support in the ... NF. , Neurofibromatosis, NF, is a genetic disorder that causes tumors to grow ...
(Date:5/17/2016)... ... May 17, 2016 , ... Yukon Medical, a ... BD (Becton, Dickinson and Company) to receive its Global Product Innovation Supplier of ... have made significant contributions to advancing or supporting key BD initiatives, products, processes, ...
(Date:5/17/2016)... Angeles, California (PRWEB) , ... May 17, 2016 ... ... intact testicular tissue prior to freezing, allowing sperm cells adequate time to move ... incubation temperature of 30°C. These combined practices lead to improved post-thaw outcomes for ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
Breaking Biology News(10 mins):